Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook

Marcelien H.E. Callenbach; Lldikó Ádám; Rick A. Vreman; Bertalan Németh; Zoltán Kaló; Wim G. Goettsch

doi:10.1016/j.drudis.2022.103433

Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook

Marcelien H.E. Callenbach, Lldikó Ádám, Rick A. Vreman, Bertalan Németh, Zoltán Kaló, Wim G. Goettsch^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

There is growing interest in innovative reimbursement and payment models in Central and Eastern European (CEE) and Middle Eastern (ME) countries. A questionnaire was sent to payers from CEE and ME countries regarding the current use of, future preferences for and perceived barriers with these models. Twenty-seven healthcare payers from 11 countries completed the survey. Results showed participants preferred using outcome-based reimbursement models and delayed payment models more often; however, currently they are rarely applied. Barriers hindering implementation were mostly related to IT and data infrastructure, measurement issues, transaction costs and the administrative burden. Given these barriers highlighted in our study, policymakers should focus on the development of an implementation framework with contract templates for the preferred reimbursement and payment schemes to aid the feasibility of a successful implementation.

Original language	English
Article number	103433
Pages (from-to)	1-9
Number of pages	9
Journal	Drug Discovery Today
Volume	28
Issue number	1
DOIs	https://doi.org/10.1016/j.drudis.2022.103433
Publication status	Published - 1 Jan 2023

Bibliographical note

Funding Information:
The HTx project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 825162. The content of this paper reflects only the HTx group’s views, and the European Commission is not liable for any use that might be made of the information contained herein. The article was prepared with the professional support of the Doctoral Student Scholarship Program of the Co-operative Doctoral Program of the Ministry of Innovation and Technology financed from the National Research, Development and Innovation Fund, Hungary. This project was funded by the Dutch National Health Care Institute as part of the Academic Living Lab for Health Technology Assessment.

Funding Information:
Funding, The HTx project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 825162. The content of this paper reflects only the HTx group's views, and the European Commission is not liable for any use that might be made of the information contained herein. The article was prepared with the professional support of the Doctoral Student Scholarship Program of the Co-operative Doctoral Program of the Ministry of Innovation and Technology financed from the National Research, Development and Innovation Fund, Hungary. This project was funded by the Dutch National Health Care Institute as part of the Academic Living Lab for Health Technology Assessment. Disclaimer, The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the agencies or organisations with which the authors are affiliated.

Publisher Copyright:
© 2022 The Authors

Funding

The HTx project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 825162. The content of this paper reflects only the HTx group’s views, and the European Commission is not liable for any use that might be made of the information contained herein. The article was prepared with the professional support of the Doctoral Student Scholarship Program of the Co-operative Doctoral Program of the Ministry of Innovation and Technology financed from the National Research, Development and Innovation Fund, Hungary. This project was funded by the Dutch National Health Care Institute as part of the Academic Living Lab for Health Technology Assessment. Funding, The HTx project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 825162. The content of this paper reflects only the HTx group's views, and the European Commission is not liable for any use that might be made of the information contained herein. The article was prepared with the professional support of the Doctoral Student Scholarship Program of the Co-operative Doctoral Program of the Ministry of Innovation and Technology financed from the National Research, Development and Innovation Fund, Hungary. This project was funded by the Dutch National Health Care Institute as part of the Academic Living Lab for Health Technology Assessment. Disclaimer, The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the agencies or organisations with which the authors are affiliated.

Keywords

Central and Eastern Europe
Delayed payment
Managed entry agreements
Middle East
Outcome-based reimbursement
Pharmaceutical reimbursement

Access to Document

10.1016/j.drudis.2022.103433Licence: CC BY

1-s2.0-S1359644622004263-mainFinal published version, 650 KBLicence: CC BY

Cite this

@article{7ee855a8b2f04583b8490206e1fbb155,

title = "Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook",

abstract = "There is growing interest in innovative reimbursement and payment models in Central and Eastern European (CEE) and Middle Eastern (ME) countries. A questionnaire was sent to payers from CEE and ME countries regarding the current use of, future preferences for and perceived barriers with these models. Twenty-seven healthcare payers from 11 countries completed the survey. Results showed participants preferred using outcome-based reimbursement models and delayed payment models more often; however, currently they are rarely applied. Barriers hindering implementation were mostly related to IT and data infrastructure, measurement issues, transaction costs and the administrative burden. Given these barriers highlighted in our study, policymakers should focus on the development of an implementation framework with contract templates for the preferred reimbursement and payment schemes to aid the feasibility of a successful implementation.",

keywords = "Central and Eastern Europe, Delayed payment, Managed entry agreements, Middle East, Outcome-based reimbursement, Pharmaceutical reimbursement",

author = "Callenbach, {Marcelien H.E.} and Lldik{\'o} {\'A}d{\'a}m and Vreman, {Rick A.} and Bertalan N{\'e}meth and Zolt{\'a}n Kal{\'o} and Goettsch, {Wim G.}",

note = "Funding Information: The HTx project has received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation programme under grant agreement no. 825162. The content of this paper reflects only the HTx group{\textquoteright}s views, and the European Commission is not liable for any use that might be made of the information contained herein. The article was prepared with the professional support of the Doctoral Student Scholarship Program of the Co-operative Doctoral Program of the Ministry of Innovation and Technology financed from the National Research, Development and Innovation Fund, Hungary. This project was funded by the Dutch National Health Care Institute as part of the Academic Living Lab for Health Technology Assessment. Funding Information: Funding, The HTx project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 825162. The content of this paper reflects only the HTx group's views, and the European Commission is not liable for any use that might be made of the information contained herein. The article was prepared with the professional support of the Doctoral Student Scholarship Program of the Co-operative Doctoral Program of the Ministry of Innovation and Technology financed from the National Research, Development and Innovation Fund, Hungary. This project was funded by the Dutch National Health Care Institute as part of the Academic Living Lab for Health Technology Assessment. Disclaimer, The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the agencies or organisations with which the authors are affiliated. Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/j.drudis.2022.103433",

language = "English",

volume = "28",

pages = "1--9",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "1",

}

TY - JOUR

T1 - Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries

T2 - A survey of their current use and future outlook

AU - Callenbach, Marcelien H.E.

AU - Ádám, Lldikó

AU - Vreman, Rick A.

AU - Németh, Bertalan

AU - Kaló, Zoltán

AU - Goettsch, Wim G.

N1 - Funding Information: The HTx project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 825162. The content of this paper reflects only the HTx group’s views, and the European Commission is not liable for any use that might be made of the information contained herein. The article was prepared with the professional support of the Doctoral Student Scholarship Program of the Co-operative Doctoral Program of the Ministry of Innovation and Technology financed from the National Research, Development and Innovation Fund, Hungary. This project was funded by the Dutch National Health Care Institute as part of the Academic Living Lab for Health Technology Assessment. Funding Information: Funding, The HTx project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 825162. The content of this paper reflects only the HTx group's views, and the European Commission is not liable for any use that might be made of the information contained herein. The article was prepared with the professional support of the Doctoral Student Scholarship Program of the Co-operative Doctoral Program of the Ministry of Innovation and Technology financed from the National Research, Development and Innovation Fund, Hungary. This project was funded by the Dutch National Health Care Institute as part of the Academic Living Lab for Health Technology Assessment. Disclaimer, The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the agencies or organisations with which the authors are affiliated. Publisher Copyright: © 2022 The Authors

PY - 2023/1/1

Y1 - 2023/1/1

N2 - There is growing interest in innovative reimbursement and payment models in Central and Eastern European (CEE) and Middle Eastern (ME) countries. A questionnaire was sent to payers from CEE and ME countries regarding the current use of, future preferences for and perceived barriers with these models. Twenty-seven healthcare payers from 11 countries completed the survey. Results showed participants preferred using outcome-based reimbursement models and delayed payment models more often; however, currently they are rarely applied. Barriers hindering implementation were mostly related to IT and data infrastructure, measurement issues, transaction costs and the administrative burden. Given these barriers highlighted in our study, policymakers should focus on the development of an implementation framework with contract templates for the preferred reimbursement and payment schemes to aid the feasibility of a successful implementation.

AB - There is growing interest in innovative reimbursement and payment models in Central and Eastern European (CEE) and Middle Eastern (ME) countries. A questionnaire was sent to payers from CEE and ME countries regarding the current use of, future preferences for and perceived barriers with these models. Twenty-seven healthcare payers from 11 countries completed the survey. Results showed participants preferred using outcome-based reimbursement models and delayed payment models more often; however, currently they are rarely applied. Barriers hindering implementation were mostly related to IT and data infrastructure, measurement issues, transaction costs and the administrative burden. Given these barriers highlighted in our study, policymakers should focus on the development of an implementation framework with contract templates for the preferred reimbursement and payment schemes to aid the feasibility of a successful implementation.

KW - Central and Eastern Europe

KW - Delayed payment

KW - Managed entry agreements

KW - Middle East

KW - Outcome-based reimbursement

KW - Pharmaceutical reimbursement

UR - http://www.scopus.com/inward/record.url?scp=85142318547&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2022.103433

DO - 10.1016/j.drudis.2022.103433

M3 - Review article

C2 - 36372328

AN - SCOPUS:85142318547

SN - 1359-6446

VL - 28

SP - 1

EP - 9

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 1

M1 - 103433

ER -

Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this